The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.
暂无分享,去创建一个
R. Reynolds | M. Calabrese | R. Capra | C. Romualdi | A. Scalfari | Marco Pitteri | A. Pisani | M. Castellaro | Maddalena Guandalini | Stefano Ziccardi | S. Montemezzi | R. Magliozzi | F. Pizzini | S. Rossi | A. Bajrami | S. Rasia | D. Marastoni | Agnese Tamanti | Samuele Bonomi | V. Mazziotti | A. Tamanti
[1] H. Lassmann. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis , 2019, Front. Immunol..
[2] A. Oturai,et al. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis , 2018, Multiple sclerosis.
[3] C. Gasperini,et al. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives , 2018, Multiple Sclerosis and Demyelinating Disorders.
[4] M. Bozzali,et al. CSF β-amyloid predicts prognosis in patients with multiple sclerosis , 2018, Multiple sclerosis.
[5] M. Filippi,et al. MRI in multiple sclerosis: what is changing? , 2018, Current opinion in neurology.
[6] M. Calabrese,et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis , 2018, Neurology.
[7] F. Facchiano,et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis , 2018, Annals of neurology.
[8] A. B. Lyons,et al. Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania major , 2018, Front. Immunol..
[9] M. Calabrese,et al. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study , 2017, Multiple sclerosis.
[10] E. Havrdová,et al. “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis , 2017, Multiple sclerosis.
[11] F. Berven,et al. Label‐free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis , 2016, Proteomics.
[12] P. Williamson,et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis , 2015, Annals of neurology.
[13] P. Nichelli,et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis , 2015, Journal of Neuroimmunology.
[14] H. Møller,et al. Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel , 2015, PloS one.
[15] O. Ciccarelli,et al. Exploring the origins of grey matter damage in multiple sclerosis , 2015, Nature Reviews Neuroscience.
[16] H. Møller,et al. Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis , 2014, PloS one.
[17] A. Huber,et al. Type-I Interferons Suppress Microglial Production of the Lymphoid Chemokine, CXCL13 , 2014, Glia.
[18] Richard Reynolds,et al. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. , 2013, Brain : a journal of neurology.
[19] M. Calabrese,et al. Cortical lesion load associates with progression of disability in multiple sclerosis. , 2012, Brain : a journal of neurology.
[20] David H. Miller,et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.
[21] Bruce Fischl,et al. FreeSurfer , 2012, NeuroImage.
[22] A. Bar-Or,et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro , 2012, Journal of Neuroimmunology.
[23] B. Scheithauer,et al. Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.
[24] Bruce Fischl,et al. Avoiding asymmetry-induced bias in longitudinal image processing , 2011, NeuroImage.
[25] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[26] O. Ciccarelli,et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI , 2011, Neurology.
[27] N. Esen,et al. The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system , 2010, Brain, Behavior, and Immunity.
[28] R. Reynolds,et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.
[29] G. Comi,et al. Freedom from disease activity in multiple sclerosis , 2010, Neurology.
[30] J. Fleming,et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.
[31] F. Barkhof,et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial , 2008, The Lancet Neurology.
[32] Hans Lassmann,et al. The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.
[33] F. Aloisi,et al. Lymphoid neogenesis in chronic inflammatory diseases , 2006, Nature Reviews Immunology.
[34] Hans Lassmann,et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.
[35] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[36] R. Reynolds,et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.